BioSpace News Archive

Lyra Therapeutics, Inc. announced that new LYR-210 data analyses from the Phase 2 LANTERN study will be presented at the 68th Annual Meeting of the American Rhinologic Society in Philadelphia.

Concert Pharmaceuticals, Inc. announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1.

Cardiff Oncology, Inc. announced new preclinical and clinical data from its program in KRAS-mutated mCRC.

ImCheck Therapeutics presented promising updated safety and patient response data from the completed dose escalation combination cohort of its ongoing EVICTION clinical trial during an oral session at the European Society for Medical Oncology Congress currently being held in Paris, France.

Bicara Therapeutics presented new clinical data from the ongoing Phase 1/1b trial of BCA101, an EGFR / TGF-β bifunctional antibody, as a monotherapy and in combination with pembrolizumab.

SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, are being presented as a late-breaking oral presentation during a Presidential Symposium at the European Society for Medical Oncology Congress 2022.

James Johnston, an innovative executive with extensive financial and strategic experience with global organizations, has joined the board of directors of Greyledge Technologies, Inc.

CatalYm, presented data from its first-in-human GDFather-1 trial at the European Society for Medical Oncology Congress 2022 held in Paris, France.

I-Mab announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed higher risk myelodysplastic syndrome, presented in an oral presentation on September 10 at the European Society for Medical Oncology Congress 2022.

Deciphera Pharmaceuticals, Inc. announced positive initial data from the single agent dose escalation portion of the Phase 1 study of DCC-3116, the Company’s first-in-class, potent, and selective small molecule switch-control kinase inhibitor of ULK1/2, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.